1. Alfieri CM, Molinari P, Cinque F, Vettoretti S, Cespiati A, Bignamini D, et al. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives. International Journal of Molecular Sciences. 25.14 (2024): 7728. [ DOI:10.3390/ijms25147728] 2. Basevi V. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2011;34:S62 - S9. [ DOI:10.2337/dc11-S062] 3. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88-98. [ DOI:10.1038/nrendo.2017.151] 4. Qiao T, Luo T, Pei H, Yimingniyazi B, Aili D, Aimudula A, et al. Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study. Cardiovascular Diabetology. 2022 Nov 1;21(1):225. [ DOI:10.1186/s12933-022-01670-x] 5. Khawaja T, Nied M, Wilgor A, Neeland IJ. Impact of Visceral and Hepatic Fat on Cardiometabolic Health. Current Cardiology Reports. 2024;26:1297 - 307. [ DOI:10.1007/s11886-024-02127-1] 6. Oh R, Kim G, Lee K-n, Cho SH, Kim JY, Kim S, et al. Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure. Cardiovascular Diabetology. 2024 Nov 1;23(1):391. [ DOI:10.1186/s12933-024-02489-4] 7. Roshanravan N, Tutunchi H, Parvizi R, Bastani S, Asghari Jafarabadi M, Faramarzi E, et al. Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study. Health Promot Perspect. 2024;14(2):161-7. [ DOI:10.34172/hpp.42568] 8. Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D, et al. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. Journal of Clinical Medicine. 2025 Jan 10;14(2):428. [ DOI:10.3390/jcm14020428] 9. Ganakumar V, Halebidu T, Goroshi M, Ghatnatti V. Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease. International Journal of Clinical Metabolism and Diabetes. 2024;1:45 - 57. [ DOI:10.1177/30502071231220779] 10. Platek AE, Szymańska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clinical and Experimental Hepatology. 2023;9:187 - 92. [ DOI:10.5114/ceh.2023.130744] 11. Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023;12(19). [ DOI:10.3390/jcm12196216] 12. Ebeid A, Mokhtar F, Martinez-Lebron V, Park S, Degann S, Payano J, et al. Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease. BMC Endocrine Disorders. 2025 Feb 27;25(1):53. [ DOI:10.1186/s12902-025-01881-9] 13. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. [ DOI:10.1016/j.jhep.2016.05.013] 14. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292. [ DOI:10.1016/j.eclinm.2023.102292] 15. Nagao H, Kashine S, Nishizawa H, Okada T, Kimura T, Hirata A, et al. Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovascular Diabetology. 2013 Jun 18;12(1):88. [ DOI:10.1186/1475-2840-12-88] 16. Mikolasevic I, Milić S, Turk Wensveen T, Grgic IH, Jakopčić I, Štimac D, et al. Nonalcoholic fatty liver disease - A multisystem disease? World Journal of Gastroenterology. 2016;22:9488 - 505. [ DOI:10.3748/wjg.v22.i43.9488] 17. Gao X, Chen T, Zhou F, Sun Y, Zhang J, Li X, et al. The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease. Cardiovascular Diabetology. 2025 May 9;24(1):200. [ DOI:10.1186/s12933-025-02758-w] 18. Salavatizadeh M, Soltanieh S, Ataei Kachouei A, Abdollahi Fallahi Z, Kord-Varkaneh H, Poustchi H, et al. Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 2023 Aug 22;14:1228072. [ DOI:10.3389/fendo.2023.1228072] 19. Zhao Y, Qie R, Han M, Huang S, Wu X, Zhang Y, et al. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis. 2021;31(7):1976-84. [ DOI:10.1016/j.numecd.2021.03.003] 20. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. [ DOI:10.1161/CIR.0000000000000973] 21. Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023 Oct 23;24(20):15473. [ DOI:10.3390/ijms242015473] 22. Luo W, Zhang J, Xu D, Zhou Y, Qu Z, Yang Q, et al. Low carbohydrate ketogenic diets reduce cardiovascular risk factor levels in obese or overweight patients with T2DM: A meta-analysis of randomized controlled trials. Front Nutr. 2022 Dec 13;9:1092031. [ DOI:10.3389/fnut.2022.1092031] 23. Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144(23):e472-e87. [ DOI:10.1161/CIR.0000000000001031] 24. Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28-34. [ DOI:10.1016/j.ejim.2023.11.012] 25. Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction associated steatotic liver disease and the heart. Hepatology. 2023 Dec 25:10-97. 26. Ferenc K, Jarmakiewicz-Czaja S, Sokal-Dembowska A, Stasik K, Filip R. Common Denominator of MASLD and Some Non-Communicable Diseases. Current Issues in Molecular Biology. 2024;46:6690 - 709. [ DOI:10.3390/cimb46070399] 27. Cho EEL, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-48. [ DOI:10.1136/gutjnl-2023-330110] 28. Chaudhary MYN, Jawwad M, Ismail M, Chaudhary MHN, Asghar A, Ahmed SA, et al. S2037 Comparative Diagnostic Accuracy of Fibrotouch and Fibroscan in Assessing Liver Fibrosis: A Systematic Review and Meta-Analysis. Official journal of the American College of Gastroenterology | ACG. 2024;119(10S). [ DOI:10.14309/01.ajg.0001037516.46225.38] 29. Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073-80. 30. Zibaeenejad F, Mohammadi SS, Sayadi M, Safari F, Zibaeenezhad MJ. Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study. BMC Cardiovasc Disord. 2022;22(1):162. [ DOI:10.1186/s12872-022-02601-0] 31. Khan HW, Imran M, Khan S, Athar MH, Tahir HB, Ali I. 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Calculation in Out-Patient Department. Pakistan Armed Forces Medical Journal. 2024;74(5):1255-9. [ DOI:10.51253/pafmj.v74i5.6958] 32. Zhou YY, Zhou XD, Wu SJ, Hu XQ, Tang B, Poucke SV, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(6):631-6. [ DOI:10.1097/MEG.0000000000001075] 33. Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024;44(10):2538-50. [ DOI:10.1111/liv.16016] 34. Lv Q, Zhao H. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis. Ann Med. 2024;56(1):2306192. [ DOI:10.1080/07853890.2024.2306192] 35. Salavatizadeh M, Soltanieh S, Poustchi H, Yari Z, Shabanpur M, Mansour A, et al. Dietary total antioxidant capacity is inversely associated with the odds of non-alcoholic fatty liver disease in people with type-2 diabetes. Frontiers in Nutrition. 2022 Nov 3;9:1037851. [ DOI:10.3389/fnut.2022.1037851] 36. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. [ DOI:10.1023/A:1005661516165] 37. Matsubayashi Y, Fujihara K, Khin L, Ferreira ED, Takabayashi S, Yamashita Y, et al. Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease. Diabetes Obes Metab. 2025;27(4):2035-43. [ DOI:10.1111/dom.16196] 38. Muzurović EM, Peng CCH, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022;79:1319 - 26. [ DOI:10.1161/HYPERTENSIONAHA.122.17982] 39. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. Bmj. 2019;367:l5367. [ DOI:10.1136/bmj.l5367] 40. Cernea S, Onisor DM, Roiban AL, Benedek T, Raț N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World Journal of Cardiology. 2024;16:580 - 94. [ DOI:10.4330/wjc.v16.i10.580] |
